



Palonosetron Update

Palonosetron is a potent, highly selective 5-HT₃-receptor antagonist with a strong receptor-binding affinity and an extended plasma half-life, in development in North America and Europe for the prevention of chemotherapy-induced nausea and vomiting (CINV). Recent highlights include:

Submission of the New Drug

Application (NDA): MGI and its partner HELSINN HEALTHCARE SA of Lugano, Switzerland, announced the submission of the NDA to the U.S. Food & Drug Administration (FDA) for Palonosetron on September 27, 2002 as planned. The clinical data contained in the NDA includes information gathered and analyzed from the successfully

completed Phase 3 clinical trials, including three randomized, double-blinded, comparative trials conducted at more than 130 clinical sites across North America and Europe, with approximately 1,800 cancer patients. Data from the first of the Phase 3 studies was previously disclosed. The North American market for 5-HT₃ antagonists is over \$1 billion and growing, and includes the CINV prevention and treatment market, which is approximately \$800 million. The marketing of Palonosetron is subject to review and approval by the FDA. Pending such approval, MGI plans to be ready to launch the drug in the United States in the second half of 2003.

See page 12 for more information.

Please direct any further questions you may have to Maggie P. Knack, Director of Investor Relations at MGI-telephone: (952) 346-4771

NEUMEGA® Contract Reminder

Oncology Associates reminds you of its contract with Wyeth/Genetics Institute. The contract provides discounted pricing for the product Neumega in 5mg Vial and 5mg Vial 7/bx quantities.

Wyeth/Genetics Institute offers a reimbursement/medical affairs hotline: 888-638-6342 for assistance in regard to your questions about billing for Neumega.



**NEUMEGA HOTLINE:
888-638-6342**

OA Product and Service Agreements

Oncology Associates offers a diverse portfolio of major pharmaceutical manufacturers' products at favorable prices to our members. In addition, OA offers several practice management services. Please see the list below for descriptions and contact information for our manufacturer and service contracts.

AMGEN

800.447.1000
Aranesp
Neulasta
Neupogen

ASPEN CONSULTING GROUP LTD.

877.238.7032
Specializes in the independent assessment of healthcare practice internal controls, operations and management.

AVENTIS

800.996.6626
(Reimbursement Hotline)
Anzemet
Taxotere

BEDFORD LABS

800.562.4797
Offers an entire suite of generic drugs including but not limited to:
Cisplatin
Cladribine
Doxorubicin
Leucovorin
Pamidronate

GLAXOSMITHKLINE

888.825.5249
Hycamtin
Navelbine
Zofran

MEDICAL SPECIALITIES

800.967.6400
Rental of oncology infusion pumps

MEDIMMUNE ONCOLOGY, INC.

877.633.4411
Ethyol

MDINTOUCH

866.774.0002
Offers a Web-based dictation, transcription and automated workflow tool for clinicians and administrators

NOVIDEA HEALTHCARE

877.503.1455
A full-service Professional Employer Organization (PEO) for healthcare providers and offers direct services in the administration of employees within clients' medical practices

PHARMION

720.564.9100
Innohep

ROCHE, INC.

973.235.5000
Kytril

WYETH/GENETICS INSTITUTE

617.876.1170
Neumega